Nat Med:阻断IL-1b或有助治疗肥胖型哮喘

2014-01-14 张笑 中国科学报

阻断小鼠肺部内一种特定免疫分子可以减轻小鼠与哮喘有关的肥胖症状,这是《自然—医学》上一项研究得出的结论。 肥胖是哮喘病的一种风险因素,升高的体重指数与哮喘的较高发病风险密切相关。虽然减肥可以减轻哮喘症状,但是目前的哮喘用药对肥胖人群作用不大,并且这类人群的哮喘患病因素仍然未知。 Dale Umetsu等人报告称高脂饮食喂养会使小鼠产生气道高反应性——哮喘的基本症状之一。高脂饮食会诱发小鼠体内的

阻断小鼠肺部内一种特定免疫分子可以减轻小鼠与哮喘有关的肥胖症状,这是《自然—医学》上一项研究得出的结论。【原文下载

肥胖是哮喘病的一种风险因素,升高的体重指数与哮喘的较高发病风险密切相关。虽然减肥可以减轻哮喘症状,但是目前的哮喘用药对肥胖人群作用不大,并且这类人群的哮喘患病因素仍然未知。

Dale Umetsu等人报告称高脂饮食喂养会使小鼠产生气道高反应性——哮喘的基本症状之一。高脂饮食会诱发小鼠体内的一种免疫细胞——巨噬细胞产生免疫系统分子白细胞介素-1b(IL-1b),进而促进另一种分子白细胞介素-17(IL-17)的分泌,最终使得气道疾病恶化。一种可以阻断IL-1b与其受体结合的临床药物可以防止IL-17的释放并缓解肥胖小鼠的气道疾病。由于生产IL-17的细胞种类已被发现存在于哮喘病人气道中,所以该研究结论意味着针对这类肥胖哮喘的治疗或可以IL-1b通路为突破点。

原文出处

Kim HY, Lee HJ, Chang YJ, Pichavant M, Shore SA, Fitzgerald KA, Iwakura Y, Israel E, Bolger K, Faul J, Dekruyff RH, Umetsu DT.Interleukin-17-producing innate lymphoid cells and the NLRP3 inflammasome facilitate obesity-associated airway hyperreactivity.Nat Med. 2014 Jan;【原文下载

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1709982, encodeId=3ebe1e0998214, content=<a href='/topic/show?id=7ac59e67604' target=_blank style='color:#2F92EE;'>#阻断#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97676, encryptionId=7ac59e67604, topicName=阻断)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b5ca31824852, createdName=41514497@qq.com, createdTime=Mon May 05 03:53:00 CST 2014, time=2014-05-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1879856, encodeId=88df18e9856ec, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Sun Apr 06 07:53:00 CST 2014, time=2014-04-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1508161, encodeId=a1bd150816133, content=<a href='/topic/show?id=8d4596248e' target=_blank style='color:#2F92EE;'>#IL-1#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9624, encryptionId=8d4596248e, topicName=IL-1)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f6cf9946833, createdName=jjjiang0202, createdTime=Thu Jan 16 04:53:00 CST 2014, time=2014-01-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1606097, encodeId=099c160609e53, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=16, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Thu Jan 16 04:53:00 CST 2014, time=2014-01-16, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1709982, encodeId=3ebe1e0998214, content=<a href='/topic/show?id=7ac59e67604' target=_blank style='color:#2F92EE;'>#阻断#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97676, encryptionId=7ac59e67604, topicName=阻断)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b5ca31824852, createdName=41514497@qq.com, createdTime=Mon May 05 03:53:00 CST 2014, time=2014-05-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1879856, encodeId=88df18e9856ec, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Sun Apr 06 07:53:00 CST 2014, time=2014-04-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1508161, encodeId=a1bd150816133, content=<a href='/topic/show?id=8d4596248e' target=_blank style='color:#2F92EE;'>#IL-1#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9624, encryptionId=8d4596248e, topicName=IL-1)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f6cf9946833, createdName=jjjiang0202, createdTime=Thu Jan 16 04:53:00 CST 2014, time=2014-01-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1606097, encodeId=099c160609e53, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=16, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Thu Jan 16 04:53:00 CST 2014, time=2014-01-16, status=1, ipAttribution=)]
    2014-04-06 liye789132251
  3. [GetPortalCommentsPageByObjectIdResponse(id=1709982, encodeId=3ebe1e0998214, content=<a href='/topic/show?id=7ac59e67604' target=_blank style='color:#2F92EE;'>#阻断#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97676, encryptionId=7ac59e67604, topicName=阻断)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b5ca31824852, createdName=41514497@qq.com, createdTime=Mon May 05 03:53:00 CST 2014, time=2014-05-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1879856, encodeId=88df18e9856ec, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Sun Apr 06 07:53:00 CST 2014, time=2014-04-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1508161, encodeId=a1bd150816133, content=<a href='/topic/show?id=8d4596248e' target=_blank style='color:#2F92EE;'>#IL-1#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9624, encryptionId=8d4596248e, topicName=IL-1)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f6cf9946833, createdName=jjjiang0202, createdTime=Thu Jan 16 04:53:00 CST 2014, time=2014-01-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1606097, encodeId=099c160609e53, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=16, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Thu Jan 16 04:53:00 CST 2014, time=2014-01-16, status=1, ipAttribution=)]
    2014-01-16 jjjiang0202
  4. [GetPortalCommentsPageByObjectIdResponse(id=1709982, encodeId=3ebe1e0998214, content=<a href='/topic/show?id=7ac59e67604' target=_blank style='color:#2F92EE;'>#阻断#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97676, encryptionId=7ac59e67604, topicName=阻断)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b5ca31824852, createdName=41514497@qq.com, createdTime=Mon May 05 03:53:00 CST 2014, time=2014-05-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1879856, encodeId=88df18e9856ec, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Sun Apr 06 07:53:00 CST 2014, time=2014-04-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1508161, encodeId=a1bd150816133, content=<a href='/topic/show?id=8d4596248e' target=_blank style='color:#2F92EE;'>#IL-1#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9624, encryptionId=8d4596248e, topicName=IL-1)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f6cf9946833, createdName=jjjiang0202, createdTime=Thu Jan 16 04:53:00 CST 2014, time=2014-01-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1606097, encodeId=099c160609e53, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=16, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Thu Jan 16 04:53:00 CST 2014, time=2014-01-16, status=1, ipAttribution=)]